Drug companies set for improved revenue growth in June quarter amid US market challenges
pharma
and healthcare sector are expected to show improved revenue and profit for the June 2025 quarter driven by a strong growth in the domestic market. Some companies may face pricing pressure in the US market due to sequentially lower Revlimid sales, used for the treatment of myeloma (a type of blood cancer). The performance for hospital chains may improve driven by a jump in operational beds.
Sun Pharmaceutical Industries
' revenue may grow in mid-single digit year-on-year, driven by market share gains in existing products. While the domestic business is expected to show traction, the US sales may moderate due to heightened competition in gRevlimid.
Explore courses from Top Institutes in
Select a Course Category
Operations Management
Leadership
Data Science
Others
Degree
MCA
Finance
Data Analytics
MBA
others
Public Policy
healthcare
Digital Marketing
Cybersecurity
CXO
Healthcare
Management
Project Management
Design Thinking
Technology
Product Management
PGDM
Data Science
Artificial Intelligence
Skills you'll gain:
Quality Management & Lean Six Sigma
Analytical Tools
Supply Chain Management & Strategies
Service Operations Management
Duration:
10 Months
IIM Lucknow
IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics
Starts on
Jan 27, 2024
Get Details
Dr Reddy's Laboratories domestic business is expected to grow on the back of rise in respiratory/derma segment. US revenue is highly dependent on the company's ability to book revenues through gRevlimid. Margin could decline slightly.
Agencies
Aurobindo Pharma
's revenue is expected to be modest on the back of decline in US sales. Penicillin-G plant's capacity utilisation improvement could drive the growth in future quarters. Margins are expected to be flattish.
For
Cipla
, US sales are expected to decline due to a price fall for gRevlimid, slight sequential drop in inhaler sales, which may be partially offset by higher Lanreotide sales. Margins may decline by 80 basis points.
Live Events
Lupin
's revenue is expected to grow more than peers, driven by strong growth in the US business amid new launches and increased contribution from existing products. Margins are also expected to expand by around 800 basis points.
Apollo Hospitals Enterprise
may report double digit growth in revenue and profit amid stable occupancy and higher revenue per bed. In addition, Keimed, a pharma distribution company,which Apollo acquired in 2024 is likely to support the overall margin performance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
31 minutes ago
- News18
ITR Filing 2025: How Are Debt Mutual Funds Taxed, How To Report Them In Your Income Tax Return?
Last Updated: If you have invested in debt mutual funds and are unsure about the tax implications or how to report them in your ITR, here's everything you need to know. ITR Filing 2025: The income tax return (ITR) filing season for the financial year 2024-25 (assessment year 2025-26) is underway. The last date for filing ITR without audit requirements is September 15, 2025. If you have invested in debt mutual funds and are unsure about the tax implications or how to report them in your ITR, here's everything you need to know. Debt mutual funds invest your money primarily in fixed-income securities like government bonds (G-Secs), corporate bonds, treasury bills, certificates of deposit, and other money market instruments. Their main goal is to generate steady income with relatively lower risk compared to equity funds. However, they are not risk-free and are subject to interest rate fluctuations and credit risk. It is also important to note that international mutual funds like those investing mainly in, let's say, US market or China market, are also treated like debt mutual funds for taxation purposes. Before April 1, 2023, debt mutual funds enjoyed a favourable tax regime. If you held them for over 3 years, gains were considered Long-Term Capital Gains (LTCG) and taxed at 20% with indexation (indexation adjusts your purchase price for inflation, lowering your taxable profit). Gains within 3 years were Short-Term Capital Gains (STCG) taxed as per your income slab. From April 1, 2023, the government removed the special tax status for debt mutual funds. Here's the current tax treatment for redemptions made in FY 2024-25 (AY 2025-26): 1. All Gains Taxed as Income : Regardless of how long you hold them (even for 10 years!), any profit you make on selling units of a debt mutual fund is added to your total income. 2. Taxed at Your Slab Rate: This combined income is then taxed according to your applicable income tax slab rate (5%, 20%, or 30%, plus cess). 3. No Indexation Benefit: The crucial benefit of indexation for long-term holdings is gone for investments made on or after April 1, 2023. 4. No Distinction Between STCG & LTCG: The old concepts of Short-Term (held less than 3 years) and Long-Term (held for 3 years or more) capital gains for tax purposes no longer exist for debt funds under the new regime. How are Equity Mutual Funds Treated? Equity-Oriented Funds (funds investing at least 65% in Indian equities) still have special tax rates. They are treated as equity investments. STCG (Held < 12 months): Gains taxed at 15% sold before July 23, 2024 and 20% if sold after July 23, 2024. LTCG (Held >= 12 months): Gains up to Rs 1.25 lakh during FY25 are tax-free. Gains exceeding Rs 1.25 lakh are taxed at 10% if sold before July 23, 2025 and 12.5% if sold after July 23, 2024. What If You Bought Before April 2023 and Sold During FY 2024-25? You get the benefit of the old tax rules, but only if you held the units for more than 3 years. Holding Period More than 3 Years (Long-Term): Your gain is Long-Term Capital Gain (LTCG) and is taxed at 20% on the indexed gain. For example: Bought in January 2020 for Rs 1,00,000. Sold in May 2024 (FY 2024-25) for Rs 1,50,000. Indexed Cost (approx) = Rs 1,00,000 (CII 2024-25 / CII 2019-20). If indexed cost is Rs 1,20,000, taxable gain = Rs 30,000. Tax = 20% of Rs 30,000 = Rs 6,000 + cess. Holding Period Less than 3 Years (Short-Term): Your gain is Short-Term Capital Gain (STCG). Added to your total income and taxed as per your slab rate (5%/20%/30% + cess). No special rate. What If You Bought After April 2023 and Sold in FY 2024-25? The new rules apply strictly. Holding period does not matter. Your entire profit (sale price minus purchase price, minus any exit load) is added to your total income. It is taxed as per your applicable income tax slab rate (5%/20%/30% + cess). No indexation benefit is available. For example, you bought in June 2023 for Rs 1,00,000. Sold in February 2025 for Rs 1,10,000. Profit = Rs 10,000. If your total income (including this Rs 10,000) falls in the 30% slab, tax on this gain = 30% of Rs 10,000 = Rs 3,000 + cess. How to Show Debt Mutual Funds in ITR-2 and ITR-3? Gains from debt mutual funds (whether under old or new rules) are always treated as 'Capital Gains" for individual investors. They are not considered 'Business Income" unless you are professionally trading mutual funds (which is rare for typical investors). Reporting in ITR-2 and ITR-3: 1. Find Schedule CG (Capital Gains): Both ITR-2 and ITR-3 have a dedicated 'Schedule CG" to report capital gains from assets like mutual funds, stocks, property. Listed Securities (Shares, Mutual Funds etc.): Report gains from debt mutual funds. Differentiate STCG and LTCG (Based on Purchase Date & Holding Period): Column 5a (STCG – Listed Securities): Report gains from debt funds sold within 3 years of purchase (if bought before April 2023) or gains from all debt funds bought after April 2023 (as they are effectively STCG under tax law now). Column 5b (LTCG – Listed Securities): Report gains only from debt funds bought before April 1, 2023, and held for more than 3 years (eligible for 20% with indexation). top videos View all It will require details like Name of the Mutual Fund Scheme, Date of Purchase, Date of Sale/Redemption, Sale Value (Redemption Amount), and Purchase Cost. It is always advisable to check your tax calculations with your financial advisor. About the Author Mohammad Haris Haris is Deputy News Editor (Business) at He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris More Stay updated with all the latest business news, including market trends, stock updates, tax, IPO, banking finance, real estate, savings and investments. Get in-depth analysis, expert opinions, and real-time updates—only on News18. Also Download the News18 App to stay updated! tags : income tax return ITR filing mutual funds view comments Location : New Delhi, India, India First Published: July 23, 2025, 17:01 IST News business » tax ITR Filing 2025: How Are Debt Mutual Funds Taxed, How To Report Them In Your Income Tax Return? Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Mint
37 minutes ago
- Mint
Indian Pharma Q1FY26: Strong domestic sales to cushion weakness in US markets
India's pharmaceutical companies are expected to deliver steady earnings growth in the June quarter, buoyed by robust domestic demand despite pricing pressure in the US on key products like Revlimid, said analysts. Aggregate revenue for the sector is forecast to rise about 9% year-on-year in Q1FY26, with Ebitda and net profit expanding about 8% and 2–6%, respectively, according to estimates from brokerages Nuvama and BNP Paribas. However, Ebitda margins may contract by 30–50 basis points due to erosion in US pricing. 'We expect US sales to decline 1% q-q (quarter-on-quarter) and remain volatile as the gRevlimid LoE (loss of exclusivity) is expected in the next few quarters and companies may race to gain volume share," BNP Paribas healthcare analyst Tausif Shaikh said in a research note dated 22 July. Indian drugmakers like Dr Reddy's, Cipla, Sun Pharma, Zydus Lifesciences, Natco Pharma and Aurobindo Pharma have been distributing generic versions of blood cancer drug Revlimid in restricted quantities in the US since March 2022, and will lose exclusivity in January 2026. This will open the market to unrestricted generic sales. '...most companies are set to face challenges in FY26/FY27 once the benefits of gRevlimid subside and margins return to normalised levels. For 1QFY26, we expect domestic formulation revenue growth to remain strong, while US business performance to remain company specific," the note said. US sales hit by price erosion In the US, which accounts for 30–40% of revenue for several Indian drugmakers, sales are projected to stay flat or grow marginally in Q1FY26. Price erosion in key generics, especially gRevlimid, remains a major drag, prompting companies to front-load shipments before further adjustments in January 2026. US sales of Aurobindo Pharma, Dr Reddy's, Cipla and Zydus Lifesciences are expected to be hit by price erosion in Revlimid, according to Nuvama. The brokerage expects 1% year-on-year growth in US sales for companies in its coverage. However, Zydus may post 4% growth in the US due to the incremental contribution of Mybetriq (Mirabegron) that is used to treat an overactive bladder. Sun Pharma's US revenue may grow 5% quarter-on-quarter, led by specialty products and higher Revlimid sales, but margins could narrow due to higher R&D and launch costs, Emkay Global analysts noted in a 15 July report. Lupin's US business is expected to gain from the Jynarque (Tolvaptan), used to treat kidney function decline. While Dr. Reddy's growth may be offset by margin pressure, BNP forecasts Cipla's US sales to remain flat, constrained by competition in Revlimid and Lanreotide. Lanreotide is used to treat acromegaly, where the body produces too much growth hormone and gastroenteropancreatic neuroendocrine tumors. Dr Reddy's is the first in the pack to kickstart Q1FY26 earnings for the pharma sector on Wednesday. Strong domestic sales The Indian pharmaceutical market saw a late surge in June 2025, with growth during the quarter primarily driven by cardiac, respiratory, CNS, and anti-diabetic therapies, said Emkay Global analysts. Indian branded formulations are expected to grow by 9–10% YoY, led by therapies such as cardiac, respiratory, CNS and anti-diabetics. BNP Paribas highlighted a strong uptick in IPM growth in June (11.5% YoY), lifting overall Q1 growth to 8.6%. Companies like Sun Pharma, Dr. Reddy's, Lupin and Cipla are forecast to outperform the industry average in India, with double-digit domestic revenue growth. Sun Pharma is expected to post its eighth consecutive quarter of double-digit India growth, while Cipla's domestic momentum is aided by a low base and recovery in the trade generics segment. The Nifty Pharma has declined 4.38% so far in 2025 against a 6.22% gain in the benchmark Nifty index.
Time of India
2 hours ago
- Time of India
Bengaluru founder says EMIs and home loans aren't mistakes—but emotional wealth, if you follow these 3 money rules
In a world where personal finance advice often sounds like cold, hard math—don't buy cars, avoid EMIs, skip that home loan—Shyam Achuthan, founder based in Bengaluru, is here to remind us that money decisions aren't always about logic. Sometimes, they're about life . In a thought-provoking post on LinkedIn, he argues that we're not spreadsheets—we're humans, driven by emotions, aspirations, and the desire for meaning in what we own. Take homeownership, for example. For someone who's spent their life shifting from one rental to another, buying a house isn't just a financial move. It's an emotional milestone. It's the comfort of waking up in your own space, the pride of seeing your name on the nameplate, and the peace of finally feeling rooted. This, Achuthan says, is emotional wealth—and it's as real as any number in your bank account. Explore courses from Top Institutes in Please select course: Select a Course Category Operations Management others Others healthcare Leadership Degree PGDM Project Management Management Product Management MCA MBA Public Policy Artificial Intelligence Cybersecurity Healthcare Finance Data Science Design Thinking CXO Data Analytics Data Science Digital Marketing Technology Skills you'll gain: Quality Management & Lean Six Sigma Analytical Tools Supply Chain Management & Strategies Service Operations Management Duration: 10 Months IIM Lucknow IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics Starts on Jan 27, 2024 Get Details The same goes for buying a car , not as a luxury flex, but as a gateway to freedom. The ability to visit your parents without scrambling for a bus, to drop your child off at school when it rains, or to take a long drive just to clear your head. Sure, it comes with a price tag—but the return is joy, convenience, and peace of mind. And those can't be measured in rupees. But what's his financial hack for this? Still, Achuthan is no stranger to smart financial planning . He suggests practical hacks, too—like opting for a used car that's just 2–3 years old. Since cars lose the most value in their first few years, this allows you to dodge heavy depreciation while still enjoying a modern ride. Smart moves don't need to cancel out meaningful ones. You Might Also Like: Bengaluru start-up founder explains how some middle-class people are silently building big wealth, without you even noticing The key, according to him, is balance. If you choose happiness, you must also choose responsibility. Want that new iPhone on a ₹10K EMI ? Then promise yourself to generate ₹10K more income next month. Start a side hustle, use your skills, take freelance gigs—build your hustle to match your spending. He even recommends a test run before taking on any big financial commitment. For a few months, set aside the equivalent of the EMI you'll owe. If your lifestyle isn't strained, you're ready. If it hurts too much, you've saved yourself from regret. That's financial foresight, not recklessness. Ultimately, Achuthan believes money isn't just about saving—it's about designing a meaningful life. If a decision pushes you to level up and adds purpose, it's not a mistake. It's a mission. He urges people to align their spending with their values—and then align their hustle with that spending. Buy the house. Get the car. Gift yourself the phone. But let each choice fuel a smarter, stronger version of you. Because, in the end, the wealthiest person isn't the one who spent the least. It's the one who lived fully, loved deeply, and figured out how to fund the journey.
